RxDoctor Payments Data

Nimesh Patel, MD

Clinical Cardiac Electrophysiology · Dallas, TXNPI 1790084283

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (43.6%), food and beverage and grants — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Boston Scientific at 32.1% of the total. Reporting peaked in 2019 at $3,081 and has fallen 91.9% since, to $249 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in TX, where the typical reported total is $27,892.

$7,638in general payments, 2019–2025

Across 84 payments — averaging $90.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Abbott$2K
  • Medtronic$2K
  • Tris Pharma Inc$307
  • AbbVie$289
  • Novartis$178
  • plus $218 from 4 others

What the payments were for

  • Grants$90112%
  • Travel & lodging$3,33144%
  • Food & beverage$3,33144%
  • Education$741%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,638 in reported general payments places this provider in the 15th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas →

Medicare billing

Part B allowed, 2024
$260,327
Medicare patients
1,333
Services billed
3,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$100,645
XareltoRivaroxaban46$39,436
Dofetilide32$11,060
EntrestoSacubitril/Valsartan13$9,031
Metoprolol Succinate89$1,240
Amiodarone Hcl18$235
Carvedilol22$159
Atorvastatin Calcium17$109
Furosemide11$68
Cephalexin15$47
Warfarin Sodium11$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$178$9,03113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Dallas

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →